Prolongation of Progesterone Supplementation in Antagonist Cycles and Pregnancy Outcomes
Primary Purpose
Infertility
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
progesterone
Sponsored by
About this trial
This is an interventional treatment trial for Infertility focused on measuring progesterone, antagonist, rec FSH, IVF, pregnancy
Eligibility Criteria
Inclusion Criteria:
- Age equal or less than 39
- Body mass index between 18-29 kg/m2
- Presence of both ovaries
- Basal hormonal values on day 2 of the cycle
- Embryotransfer day3 or day5
- 1 to 3 cycles
Exclusion Criteria:
- Endometriosis stage 3
- Polycystic ovarian syndrome
- Frozen or testicular sperm
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
stop progesterone
Arm Description
Outcomes
Primary Outcome Measures
ongoing pregnancy rate
Secondary Outcome Measures
Full Information
NCT ID
NCT01147770
First Posted
June 17, 2010
Last Updated
July 1, 2013
Sponsor
Universitair Ziekenhuis Brussel
1. Study Identification
Unique Protocol Identification Number
NCT01147770
Brief Title
Prolongation of Progesterone Supplementation in Antagonist Cycles and Pregnancy Outcomes
Official Title
The Effect of Progesterone Supplementation During Early Gestations in Patients Treated With Rec FSH/GnRH Antagonist:a Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
July 2013
Overall Recruitment Status
Completed
Study Start Date
September 2008 (undefined)
Primary Completion Date
January 2010 (Actual)
Study Completion Date
June 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universitair Ziekenhuis Brussel
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The objective of this study is to evaluate the effect of the prolongation of luteal support on the ongoing pregnancy rate (beyond 12 weeks of gestation )in recFSH/GnRH antagonist cycles.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility
Keywords
progesterone, antagonist, rec FSH, IVF, pregnancy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Actual)
8. Arms, Groups, and Interventions
Arm Title
stop progesterone
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
progesterone
Other Intervention Name(s)
utrogestan
Intervention Description
duration
Primary Outcome Measure Information:
Title
ongoing pregnancy rate
Time Frame
up to 2 years
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
39 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age equal or less than 39
Body mass index between 18-29 kg/m2
Presence of both ovaries
Basal hormonal values on day 2 of the cycle
Embryotransfer day3 or day5
1 to 3 cycles
Exclusion Criteria:
Endometriosis stage 3
Polycystic ovarian syndrome
Frozen or testicular sperm
12. IPD Sharing Statement
Learn more about this trial
Prolongation of Progesterone Supplementation in Antagonist Cycles and Pregnancy Outcomes
We'll reach out to this number within 24 hrs